Roche, AC Im­mune at­tempt to flesh out an­ti-tau Alzheimer's da­ta, but the fore­cast re­mains cloudy

AC Im­mune re­port­ed full da­ta on its lead­ing an­ti-tau an­ti­body for mild-to-mod­er­ate Alzheimer’s on Wednes­day af­ter­noon, and the com­plete pic­ture came in de­cid­ed­ly mixed.

Build­ing on pre­vi­ous­ly re­leased re­sults from Au­gust where the biotech’s se­morinemab can­di­date met one of two pri­ma­ry end­points, AC Im­mune filled in the blanks at a med­ical con­fer­ence Wednes­day. Though new analy­ses ap­peared to con­firm se­morinemab’s abil­i­ty to slow cog­ni­tive de­cline on one mea­sure, AC Im­mune said PET scans showed “no iden­ti­fi­able treat­ment ef­fect” on tau dis­tri­b­u­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER